New combo therapy aims to control relapsed myeloma
NCT ID NCT06252792
First seen Apr 06, 2026 · Last updated May 22, 2026 · Updated 10 times
Summary
This study looks at a three-drug combination (daratumumab, pomalidomide, and dexamethasone) for people with multiple myeloma that has come back after first treatment. About 50 adults will take part to see how well the drugs control the cancer and delay further relapse. The goal is to manage the disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The First Hospital of Jilin University
RECRUITINGChangchun, Jilin, 130000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.